Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
HOME > BUSINESS
BUSINESS
- PD-1, PD-L1 Inhibitors Could Carve Out 750 Billion Yen Market in Japan: Citi Analyst
January 28, 2015
- Takeda Launches Fomepizole
January 28, 2015
- Galderma Terminates Comarketing Agreement with Sato Pharmaceutical for Pekiron Cream
January 28, 2015
- Torii Files NDA for Sublingual Tablet for Mite Allergic Rhinitis
January 28, 2015
- Santen’s Dry Eye Treatment Receives Positive Opinion from CHMP
January 28, 2015
- Cost of Producing Antibody Drugs Remains High Despite Improvement in Culture Efficiency: Kyowa Kirin
January 27, 2015
- Xtandi Significantly Prolongs PFS in PII Study in Europe, US: Astellas
January 27, 2015
- Senshio Approved in Europe for Treatment of Symptomatic Vulvar, Vaginal Atrophy: Shionogi
January 26, 2015
- Takara Bio to Initiate Clinical Trial for Anticancer Agent HF10 in Japan
January 26, 2015
- US FDA Advisory Committee Recommends Approval of Astellas’s Azole Antifungal Agent
January 26, 2015
- Nihon Chouzai Confident of Continuing Early Price Settlements
January 23, 2015
- Open Tenders Good Example of Early Price Settlements: Qol Exec
January 22, 2015
- Lifestyle Disease-Related Medical Spending Must Be Pruned: Nobelpharma Pres.
January 22, 2015
- Medical System Network President Calls for Scrapping Fee Cut Rule
January 21, 2015
- Sakura Finetek Japan to Participate in Cervical Cancer Screening Project in Kazakhstan
January 21, 2015
- Meiji Seika Pharma Licenses Darinaparsin from Solasia Pharma in Japan
January 20, 2015
- Sanofi Launches Allegra Dry Syrup for Pediatric Patients Aged 6 Months and Older
January 20, 2015
- Pharma Bigwigs Stress Importance of Early Patent Strategies
January 19, 2015
- Foreign-Affiliated Pharmas Looking to Make “Sure Investments” to Avoid Risk of Discontinued Development: PhRMA Official
January 19, 2015
- Mr Plata Named as AbbVie G.K.’s New President
January 19, 2015
ページ
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
Takeda Pharmaceutical’s overseas sales ratio has reached 90.9%, exceeding 90% for the first time though only in the first half…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
A Japanese health ministry panel on November 28 agreed on a plan to legally require pharma companies to set up…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…